Front Matter

Pages i-vii

PDF

Basic Hematopoiesis and Leukemia Stem Cells

• William Y. K. Hwang, Sudipto Bari, Lai Guan Ng, Koji Itahana, Shang Li, Javier Yu Peng Koh et al.

Pages 1-12

Modern Classification of Acute and Chronic Leukemias: Integrating Biology, Clinicopathologic Features, and Genomics

• Harinder Gill

Pages 13-21

Molecular Techniques in the Diagnosis and Monitoring of Acute and Chronic Leukaemias

• Ho-Wan Ip, Wing-Fai Tang

Pages 23-45

Flow Cytometric Techniques in the Diagnosis and Monitoring of Acute Leukaemias

• Melissa G. Ooi, Pak Ling Lui, Te Chih Liu, Shir Ying Lee

Pages 47-59

Genomic Landscape and Risk Stratification of Acute Myeloid Leukemia

• Hsin-An Hou

Pages 61-89

Frontline Management of Acute Myeloid Leukaemia Eligible for Intensive Chemotherapy

• Sudhir Tauro, Nigel H. Russell

Pages 91-110

Frontline Management of Elderly Acute Myeloid Leukemia Ineligible for Intensive Treatment

• Yin-Jun Lou, Jie Jin, Hong-Hu Zhu

Pages 111-118

Management of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia

• Jan Philipp Bewersdorf, Amer M. Zeidan

Pages 119-128

Management of Relapsed or Refractory AML

• Harinder Gill

Pages 129-132

The Role of BCL-2/MCL-1 Targeting in Acute Myeloid Leukemia

• Kenny Tang, Steven M. Chan

Pages 133-145

Role of IDH1/IDH2 Inhibitors in AML

• Harinder Gill

Pages 147-149

Next-Generation FLT3 Inhibitors for the Treatment of FLT3-Positive AML

• Harinder Gill

Pages 151-158

Allogeneic Hematopoietic Stem Cell Transplantation for AML

• Yu-Qian Sun, Xiao-Jun Huang

Pages 159-165

Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

• Yong-Xian Hu, Hong-Hu Zhu

Pages 167-174

Immunotherapeutic Targeting of AML

• Ibraheem Motabi, Bader Alahmari, John F. DiPersio

Pages 175-191

In the Pipeline: Emerging Therapy for Acute Myeloid Leukaemia

• Harinder Gill, Amber Yip

Pages 193-242

Frontline Management of Acute Promyelocytic Leukemia

• Harinder Gill

Pages 243-249

Management of Relapsed Acute Promyelocytic Leukemia and the Role of Hematopoietic Stem Cell Transplantation

• Harinder Gill

Pages 251-254

Genomic Landscape of Acute Lymphoblastic Leukemia (ALL): Insights to Leukemogenesis, Prognostications, and Treatment

• Sin Chun-fung

Pages 255-275

Management of Adolescent and Young Adults with Acute Lymphoblastic Leukaemia

• Chi-Kong Li, Frankie Wai-Tsoi Cheng, Daniel Ka-Leung Cheuk

Pages 277-283

Management of Older Patients with Acute Lymphoblastic Leukemia

• Xiao-Xia Hu, Hong-Hu Zhu

Pages 285-288

Management of Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia

• Philip R. Selby, Kirsty M. Sharplin, Michael P. Osborn, David T. Yeung

Pages 289-310

Management of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (Ph-Like ALL)

• Thai Hoa Tran, Sarah K. Tasian

Pages 311-327

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia

• Meng Lv, Wei Sun, Xiao-Jun Huang

Pages 329-339

Immunotherapy for ALL

• Wei Sun, Xiao-Jun Huang

Pages 341-352

In the Pipeline—Emerging Therapy for ALL

• Harinder Gill, Cherry Chu, Yammy Yung

Pages 353-394

Inherited/Genetic Predisposition to MDS and AML

• Lucy A. Godley

Pages 395-404

Clonal Hematopoiesis and Its Functional Implications in MDS/AML

• Harinder Gill

Pages 405-407

Therapy-Related MDS/AML and the Role of Environmental Factors

• Maria Teresa Voso, Giulia Falconi

Pages 409-420

Prognostic Indicators in MDS and CMML

• Harinder Gill, Yammy Yung, Cherry Chu, Amber Yip

Pages 421-435

Treatment Algorithm of Myelodysplastic Syndromes

• Anne Sophie Kubasch, Uwe Platzbecker

Pages 437-442

Treatment Algorithm of CMML and Other Adult MDS/MPN Subtypes

• Florence Rabian, Raphael Itzykson

Pages 443-460

Novel Strategies to Manage Cytopenia in Low-Risk MDS

• Valeria Santini

Pages 461-467

Allogeneic Hematopoietic Stem Cell Transplantation for MDS and CMML: When and How?

• Harinder Gill, Yammy Yung, Cherry Chu, Amber Yip

Pages 469-475

In the Pipeline: Emerging Therapy for MDS and MDS/MPN

• Harinder Gill, Emily Lee, Pinky Mo

Pages 477-500

Molecular Landscape and Personalized Prognostic Prediction of MPNs

• Harinder Gill, Yammy Yung, Cherry Chu, Amber Yip

Pages 501-513

Treatment Algorithm for Polycythemia Vera

• Jeanne Palmer, Ruben Mesa

Pages 515-521

Treatment Algorithm of Essential Thrombocythemia

• Jennifer O’Sullivan, Anna Green, Claire Harrison

Pages 523-538

Prognostic Models for Primary and Secondary Myelofibrosis

• Harinder Gill, Garret Leung

Pages 539-541

Treatment Algorithm for Primary and Secondary Myelofibrosis

• Harinder Gill, Garret Leung

Pages 543-547

Diagnosis and Management of Prefibrotic Primary Myelofibrosis (Pre-PMF)

• Tiziano Barbui, Alessandra Carobbio, Jürgen Thiele

Pages 549-557

Interferons in Myeloproliferative Neoplasms

• Lucia Masarova, Srdan Verstovsek

Pages 559-565

JAK Inhibitors for the Management of Myeloproliferative Neoplasms

• Prithviraj Bose, Srdan Verstovsek

Pages 567-576

Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: When and How?

• Nicolaus Kröger

Pages 577-583

Thrombosis and Myeloproliferative Neoplasms

• Alexandre Guy, Chloé James

Pages 585-594

Eosinophilic Disorders and Systemic Mastocytosis

• Harinder Gill, Yammy Yung, Cherry Chu, Amber Yip

Pages 595-606

In the Pipeline: Emerging Therapy for Classical Ph-Negative MPNs

• Harinder Gill, Yammy Yung

Pages 607-623

Current Guidelines and Treatment Algorithm of Chronic Myeloid Leukemia

• Carol Cheung Yuk Man

Pages 625-633

Treatment-Free Remission in Chronic Myeloid Leukemia

• Naranie Shanmuganathan, David M. Ross

Pages 635-647

Treatment Options in CML Resistant or Intolerant to Second-Generation Tyrosine Kinase Inhibitors

• Carol Cheung Yuk Man

Pages 649-652

Allogeneic Hematopoietic Cell Transplantation in CML: When and How?

• Fiona Fernando, Andrew J. Innes

Pages 653-661

In the Pipeline: Emerging Therapy for CML

• Harinder Gill, Emily Lee, Pinky Mo

Pages 663-684